HHS and FDA to Reevaluate Safety Measures for Abortion Medication

Share this article on: Facebook | Twitter | Print this page.

According to Live Action News, Robert F. Kennedy, Jr., the Health and Human Services (HHS) Secretary, and FDA Commissioner Martin Makary have sent letters to select state attorneys general (AGs). These letters inform the AGs that the Food and Drug Administration (FDA) will carry out an extensive review of the safety of the abortion pill.

Robert F. Kennedy, Jr., appointed by President Trump to lead HHS, made a commitment to reinstate pro-life policies in the department. In addition, six pro-life groups along with over 20 state AGs appealed to HHS and the FDA over the summer to restore the safeguards of abortion pills, which were substantially relaxed under the Biden administration. Kennedy and Makary subsequently responded to these AGs, confirming a comprehensive review of the safety of the abortion pill.

The Gateway Pundit shared a copy of this letter, responding to the July 31 letter from 22 AGs who were urging the FDA to reinstate the safety regulations for the abortion pill. The letter from Kennedy and Makary stated their commitment to studying the reported harmful consequences of mifepristone in order to ensure its safe use. This includes conducting a review of the evidence of the safety and effectiveness of this drug.

According to a recent analysis conducted by the Ethics and Public Policy Center (EPPC), serious adverse complications occurred 22 times more frequently in women who took the abortion pill than the rate reported on the FDA label for mifepristone 200 mg.

The abortion pill (mifepristone 200mg), approved by the FDA in 2000 with safety protocols, has been gradually diffused under both the Obama and Biden-Harris administrations. Any examination of its safety is long overdue.

This article was originally published by Live Action News.